Scinai Immunotherapeutics Ltd - American Depositary Shares — balance (NASDAQ:SCNI)

Financials

Activos totales 17.7 M32.03 M27.07 M17.47 M13.45 M11.63 M Total de pasivos 22.24 M24.52 M28.83 M22.04 M3.47 M3.52 M Capital total -4.54 M7.5 M-1.76 M-4.57 M9.98 M8.1 M Total de pasivos y patrimonio neto 17.7 M32.03 M27.07 M17.47 M13.45 M11.63 M Deuda total ——21.7 M20.2 M403 K294 K Deuda neta ——7.63 M15.33 M-1.56 M-1.37 M

Scinai Immunotherapeutics Ltd - American Depositary Shares

BiondVax Pharmaceuticals Ltd. is an Israeli biopharmaceutical company focused on developing and manufacturing immunotherapeutic products, primarily for the treatment of infectious diseases and autoimmune diseases. In collaboration with the Max Planck Institute for Multidisciplinary Sciences and the University Medical Center Göttingen, both in Germany, BiondVax develops nanosized antibody therapies for diseases such as COVID-19, asthma and psoriasis.

SCNI

Financials

Scinai Immunotherapeutics Ltd - American Depositary Shares

Noticias

Scinai completa reorganización corporativa y separa unidad CDMO

Scinai recibe ampliación de subvención para sistema robótico

Scinai receives expanded grant for robotic manufacturing system

Scinai reporta crecimiento de ingresos mientras se expande su negocio CDMO

Scinai reports revenue growth as CDMO business expands

Scinai Immunotherapeutics programa reunión anual para el 22 de diciembre

Scinai Immunotherapeutics programa reunión anual para el 22 de diciembre

Scinai Immunotherapeutics schedules annual meeting for December 22

Scinai recibe subvención de $246,000 para ampliar fabricación biotecnológica

Scinai receives $246,000 grant to expand biotech manufacturing

Scinai Immunotherapeutics stock soars on promising skin disease drug data

Scinai’s PC111 antibody shows promise for pemphigus treatment